Birgitta Lehtinen

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Background. Inhibitors of fibroblast growth factor receptors (FGFRs) have recently arisen as a promising treatment option for patients with FGFR alterations. Gene fusions involving FGFR3 and transforming acidic coiled-coil protein 3 (TACC3) have been detected in diffuse gliomas and other malignancies, and fusion-positive cases have responded well to FGFR(More)
  • 1